Feb 10, 2021: Read about two more databases from Singapore
The Singapore Myocardial Infarction Registry (SMIR) and the Singapore Stroke Registry (SSR) are two of several databases managed by the National Registry of Diseases Office (NRDO).
Singapore Myocardial Infarction Registry (Singapore) **
Database Contact Data
National Registry of Diseases Office
Address:
Health Promotion Board
3 Second Hospital Avenue
Level 5
Singapore 168937
Email: HPB_SERVICENRDO@hpb.gov.sg
Phone: +65 6435 3077 / +65 6435 3091 / +65 6435 3039
Alternate Contact
N/A
References of Studies Using/Describing Database
1. Wong HJ, Yau CE, Low CE, Lee ARYB, Au JXY, Teo YH, et al. Acute myocardial infarction in head and neck cancer patients and survivors: a population-based cohort study of patient, disease, and treatment factors. Clin Oncol (R Coll Radiol). 2026;59:104334.
2. Gurung RL, Zheng H, Tan JLI, Wu H, Liu S, Dorajoo R, et al. Plasma proteins associated with incident acute myocardial infarction in Asians with type 2 diabetes. JACC Asia. 2026 Aug 11. Online ahead of print.
3. National Registry of Diseases Office. Singapore Myocardial Infarction Registry annual report 2023. Singapore: Health Promotion Board; 2025 Oct.
4. Wong HJ, Teo FJJ, Yau CE, Low CE, Low JJY, Koh TS, et al. Prognosis of patients with ST-elevation myocardial infarction presenting to the emergency department without chest pain: a retrospective nationwide cohort study. Heart. 2026 Jun 18. Online ahead of print.
5. Cao G, Weight N, Jauhari SM, Chong B, Rashid M, Chen Y, et al. Myocardial infarction without standard modifiable risk factors from 2025-2040: forecast analysis of a multinational, population-based study. JACC Asia. 2026;6(6):910-925.
6. Wong HJ, Toh KZX, Low CE, Yau CE, Teo YH, Teo YN, et al. Guideline-directed medical therapy in nonagenarians and centenarians (≥90 years old) after first-onset myocardial infarction: a national registry study. Can J Cardiol. 2025;41(7):1372-1382.
7. Sia CH, Ko J, Zheng H, Ho AFW, Foo D, Foo LL, et al. Association of body mass index, metabolic health status and clinical outcomes in acute myocardial infarction patients: a national registry-based study. Front Cardiovasc Med. 2023;10:1142078.
8. Sia CH, Zheng H, Ko J, Ho AFW, Foo D, Foo LL, et al. Comparison of the modified Singapore myocardial infarction registry risk score with GRACE 2.0 in predicting 1-year acute myocardial infarction outcomes. Sci Rep. 2022;12:14270.
9. Koo GPY, Zheng H, Pek PP, Hughes F, Lim SL, Yeo JW, et al. Clustering of environmental parameters and the risk of acute myocardial infarction. Int J Environ Res Public Health. 2022;19(14):8476.
10. Sia CH, Ko J, Zheng H, Ho AFW, Foo D, Foo LL, et al. Comparison of mortality outcomes in acute myocardial infarction patients with or without standard modifiable cardiovascular risk factors. Front Cardiovasc Med. 2022;9:876465.
Singapore Stroke Registry (Singapore) **
Database Contact Data
National Registry of Diseases Office
Address:
Health Promotion Board
3 Second Hospital Avenue
Level 5
Singapore 168937
Email: HPB_SERVICENRDO@hpb.gov.sg
Phone: +65 6435 3077 / +65 6435 3091 / +65 6435 3039
Alternate Contact
N/A
References of Studies Using/Describing Database
1. Health Promotion Board. Singapore Stroke Registry annual report 2022. Singapore: National Registry of Diseases Office; 2025 Jan. https://www.nrdo.gov.sg/publications/singapore-stroke-registry-annual-report-2022/
2. Lim MJR, Zheng H, Zhang Z, Sia CH, Tan BYQ, Ong MEH, et al. Trends in hemorrhagic stroke incidence and mortality in a National Stroke Registry of a multi-ethnic Asian population. Eur Stroke J. 2024 Mar;9(1):189-199.
3. Koo GP, Zheng H, Aik JC, Tan BY, Sharma VK, Sia CH, et al. Clustering of environmental parameters and the risk of acute ischaemic stroke. Int J Environ Res Public Health. 2023 Mar 11;20(6):4979.
4. Ho JS, Sia CH, Zheng H, Tan BY, Ho AF, Yeo LL, et al. Interplay between post-myocardial infarction ejection fraction and atrial fibrillation: implications for ischemic stroke. Eur Heart J. 2023 Feb;44(Suppl 1):ehac779.060.
5. Koh YS, Subramaniam M, Matchar DB, Hong SI, Koh GC. The associations between caregivers’ psychosocial characteristics and caregivers’ depressive symptoms in stroke settings: a cohort study. BMC Psychol. 2022 Dec;10(1).
6. Ho AF, Tan BY, Zheng H, Leow AS, Pek PP, Liu N, et al. Association of air pollution with acute ischemic stroke risk in Singapore: a time-stratified case-crossover study. Int J Stroke. 2022 Oct;17(9):983-989.
7. Liu X, Tou NX, Gao Q, Gwee X, Wee SL, Ng TP. Frailty and risk of cardiovascular disease and mortality. PLoS One. 2022 Sep 19;17(9):e0272527.
8. Tan BY, Ho JS, Ho AF, Pek PP, Leow AS, Raju Y, et al. Ambient air pollution and acute ischemic stroke—effect modification by atrial fibrillation. J Clin Med. 2022 Sep 15;11(18):5429.
9. Ho AF, Lim MJ, Zheng H, Leow AS, Tan BY, Pek PP, et al. Association of ambient air pollution with risk of hemorrhagic stroke: a time-stratified case crossover analysis of the Singapore stroke registry. Int J Hyg Environ Health. 2022 Mar;240:113908.
10. Tan TH, Zheng H, Cheo T, Tey J, Soon YY. Risk of stroke in nasopharyngeal cancer survivors: a national registry-based population cohort study. Neurology. 2022 Jan 11;98(2):e115-e124.
Feb 8, 2021: Read all about UK’s Systemic Anti-Cancer Therapy (SACT) Database
The SACT database is a population-based resource of SACT activity reported routinely by National Health Service (NHS) trusts in England. Data are collected since 2012 on the SACT treatments of adult and paediatric patients, delivered in secondary and tertiary settings with the intention of improving survival, delaying further cancer progression or development and improving disease-free or progression-free survival.
Systemic Anti-Cancer Therapy Database (SACT) (United Kingdom) **
Database Contact Data
SACT
UNITED KINGDOM
Email 1: ndrs.datasets@nhs.net
Email 2: NDRSenquiries@nhs.net
Website: www.chemodataset.nhs.uk
Phone: +44 0113 518 0696
Alternate Contact
Contact form: https://digital.nhs.uk/ndrs/ndrs-contact-page
References of Studies Using/Describing Database
1. Mahmoudpour SH, Knott C, Kearney M, Russo L, Verpillat P. Factors associated with receipt of systemic anticancer treatment for locally advanced or metastatic urothelial carcinoma in England: a population-based study. Urol Oncol. 2024 Dec;42(12):451.e11-451.e18.
2. Tabacchi F, Oberai R, Parmar K, Oxley L, Coe S, Iatridi V, et al. Documentation of anthropometrics in people with cancer: a cross-site collaboration audit in four hospital settings in the UK. Support Care Cancer. 2024;32(11):720.
3. Han L, Josephs D, Boyle J, Sullivan R, Rigg A, van der Meulen J, et al. Hospital factors influencing the mobility of patients for systemic therapies in breast and bowel cancer in the metastatic setting: a national population-based evaluation. Clin Oncol (R Coll Radiol). 2024;36(10):e398-e407.
4. Lythgoe MP, Emhardt AJ, Naci H, Krell J, Sullivan R, Aggarwal A. Efficacy and safety of interim oncology treatments introduced for solid cancers during the COVID-19 pandemic in England: a retrospective evidence-based analysis. Lancet Reg Health Eur. 2024;46:101062.
5. Wills L, Nagarwalla D, Pearson C, McPhail S, Hinchliffe R, Sharpless B, et al. Estimating surgery, radiotherapy and systemic anti-cancer therapy treatment costs for cancer patients by stage at diagnosis. Eur J Health Econ. 2024;25(5):763-774.
6. Hughes NF, Cromie KJ, Feltbower RG, McCabe MG, Stark D. Delivered relative dose intensity in adolescent and young adult germ cell tumours in England: assessment of data quality and consistency from clinical trials compared to national cancer registration data. Int J Cancer. 2024;154(5):816-829.
7. Norris RP, Dew R, Greystoke A, Todd A, Sharp L. Socio-economic inequalities in novel NSCLC treatments during the era of tumor biomarker guided therapy: a population-based cohort study in a publicly funded healthcare system. J Thorac Oncol. 2023.
8. Gannon MR, Park MH, Miller K, Dodwell D, Horgan K, Clements K, et al. Concordance of cancer drug therapy information derived from routinely collected hospital admissions data and the Systemic Anti-Cancer Therapy (SACT) dataset, for older women diagnosed with early invasive breast cancer in England. Cancer Epidemiol. 2023;83:102337.
9. Kang J, Cairns J. Don't think twice, it's all right: using additional data to reduce uncertainty regarding oncologic drugs provided through managed access agreements in England. Pharmacoecon Open. 2023;7(1):77-91.
10. Hassan S, Miles A, Rachet B, Morris M. Variations in the type of adjuvant chemotherapy among stage III colon cancer patients in England. J Gastrointest Cancer. 2023.
1/27/21 Read all about the Singapore Cancer Registry on B.R.I.D.G.E. TO DATA
The Singapore Cancer Registry (SCR), one of the oldest and most established registries, was set up in 1968 to provide information on cancer trends in Singapore. Over the last 50+ years, SCR, a comprehensive, population-based national cancer registry, has collated data on all cancers by histological diagnosis as well as notification by doctors through clinical assessment in Singapore.
Singapore Cancer Registry (Singapore) **
Database Contact Data
National Registry of Diseases Office
Address:
Health Promotion Board
3 Second Hospital Avenue
Level 5
Singapore 168937
Email: HPB_SERVICENRDO@hpb.gov.sg
Phone: +65 6435 3077 / +65 6435 3091 / +65 6435 3039
Alternate Contact
N/A
References of Studies Using/Describing Database
1. Health Promotion Board. Singapore Cancer Registry. Annual Report 2023. 2026 Jan. https://www.nrdo.gov.sg/docs/librariesprovider3/default-document-library/singapore-cancer-registry-annual-report-2023.pdf?sfvrsn=a4703e8e_2
2. Health Promotion Board. Singapore Cancer Registry. Annual Report 2022. 2024 Sep. https://www.nrdo.gov.sg/docs/librariesprovider3/default-document-library/scr-ar-2022_web-report.pdf?sfvrsn=a9eb8c10_1
3. Thomas CE, Adibi JJ, Kuipers AL, Diergaarde B, Luu HN, Jin A, Koh WP, Gao YT, Adams-Haduch J, Wang R, Lokshin A. Soluble CD137 and risk of hepatocellular carcinoma: nested case–control studies in cohorts in Shanghai and Singapore. British Journal of Cancer. 2023 Jun 15;128(11):2081-8.
4. Peres MA, Huihua L, Antunes JL, Perea LM, Iyer NG, Peres KG. Time trend and Age-Period-Cohort analysis of potentially HPV-related oral and pharyngeal cancer incidence in Singapore between 1968 and 2017. Oral Oncology. 2023 Jan 1;136:106272.
5. Yu YC, Paragomi P, Jin A, Wang R, Schoen RE, Koh WP, Yuan JM, Luu HN. Dietary nonstarch polysaccharide intake and risk of colorectal cancer: findings from the Singapore Chinese health study. Cancer research communications. 2022 Oct 31;2(10):1304-11.
6. Soo R, Mery L, Bardot A, Kanesvaran R, Keong TC, Pongnikorn D, Prasongsook N, Hutajulu SH, Irawan C, Ab Manan A, Thiagarajan M. Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries. ESMO open. 2022 Oct 1;7(5):100560.
7. Htun HL, Lian W, Wong J, Tan EJ, Foo LL, Ong KH, Lim WY. Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017. Cancer Epidemiology. 2022 Aug 1;79:102175.
8. Sheng LT, Jiang YW, Pan A, Koh WP. Dietary total antioxidant capacity and mortality outcomes: The Singapore Chinese Health Study. European Journal of Nutrition. 2022 Aug;61(5):2375-82.
9. Lei M, Adambekov S, Edwards RP, Wang R, Yuan JM, Kalix E, Lopa S, Linkov F. Endometrial cancer risk factors in Singapore Chinese: a prospective cohort study. Annals of Epidemiology. 2022 Jul 1;71:9-14.
10. Paragomi P, Wang R, Jin A, Yu YC, Brand RE, Sheng LT, Pan A, Koh WP, Yuan JM, Luu H. Composite dietary antioxidant index and the risk of pancreatic cancer: Findings from a prospective cohort study. Cancer Research. 2022 Jun 15;82(12_Supplement):3667-.